BSD Medical Reports Publication of Clinical Study Results of Hyperthermia Using the BSD-2000 and Chemotherapy to Treat Advanced

  BSD Medical Reports Publication of Clinical Study Results of Hyperthermia
  Using the BSD-2000 and Chemotherapy to Treat Advanced Pancreatic Cancer
  Patients

Business Wire

SALT LAKE CITY -- February 5, 2013

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems that utilize heat therapy to treat cancer,
announced the publication of results from a clinical study on advanced
pancreatic cancer using the BSD-2000 Hyperthermia System (BSD-2000). The
study, "Gemcitabine and cisplatin combined with regional hyperthermia as
second-line treatment in patients with gemcitabine-refractory advanced
pancreatic cancer", (Int J Hyperthermia. 2013;29[1]:8-16) reported the results
of a retrospective analysis of 23 patients with advanced or metastatic
pancreatic cancer who had relapsed after first-line chemotherapy treatment.
The researchers, Tschoep-Lechner, et al., reported that hyperthermia,
delivered using the BSD-2000, combined with gemcitabine and cisplatin resulted
in low toxicity and high feasibility, even in these study patients who had a
very negative prognosis and no standard treatment options. The researchers
also reported that, despite the intrinsic limitation of a small retrospective
analysis, the results suggested clinical efficacy of hyperthermia combined
with gemcitabine and cisplatin whereas gemcitabine and cisplatin without
hyperthermia does not seem to provide a significant benefit in patients with
advanced pancreatic cancer.

In order to acquire additional data, the researchers are currently conducting
a multicenter randomized Phase III study on the use of gemcitabine and
cisplatin combined with hyperthermia compared to gemcitabine alone to treat
postoperative pancreatic cancer. The study, which will accrue 332 patients, is
led by the Department of Medical Oncology, Klinikum Grosshadern, Munich
University Medical School, Munich, Germany, with Rolf D. Issels MD PhD as
principal investigator. Participating centers for patient accrual include
Klinik Bad Trissl, Schlossbergklinik Oberstaufen, Erlangen UMS, Tübingen UMS,
Düsseldorf UMS and Charité UMS Berlin, all Germany.

Pancreatic cancer is one of the deadliest and most difficult to treat cancers
and is the fourth leading cause of cancer-related death in the U.S. and
throughout the world for both genders. Worldwide, there are approximately
278,684 patients per year diagnosed with pancreatic cancer. The median
survival is approximately 6 months for patients with metastatic disease and 10
months for patients with locally advanced disease. Advanced pancreatic cancer
patients currently have few treatment options. The risk of developing
pancreatic cancer increases as people age.

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE Marking approval is also recognized in many
countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.

Contact:

BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930
 
Press spacebar to pause and continue. Press esc to stop.